Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
16
02
2021
accepted:
28
04
2021
pubmed:
10
6
2021
medline:
24
7
2021
entrez:
9
6
2021
Statut:
ppublish
Résumé
New treatment options may lead to an increased interest in using reliable and sensitive instruments to assess health-related quality of life in people with alopecia areata (AA). The purpose of this paper is to present current knowledge about quality of life assessment in AA. The dermatology-specific Dermatology Life Quality Index (DLQI) was the most widely reported health-related quality of life instrument used in AA. Three AA-specific (Alopecia Areata Symptom Impact Scale, Alopecia Areata Quality of Life Index and Alopecia Areata Patients' Quality of Life) and three hair disease-specific instruments (Hairdex, Scalpdex and 'hair-specific Skindex-29') were identified with a range of content and validation characteristics: there is little evidence yet of the actual use of these measures in AA. Scalpdex is the best-validated hair disease-specific instrument. Further extensive validation is needed for all of the AA-specific instruments. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes recommends the use of the dermatology-specific DLQI questionnaire, hair disease-specific Scalpdex and the alopecia areata-specific instruments the Alopecia Areata Symptom Impact Scale or Alopecia Areata Quality of Life Index, despite the limited experience of their use. We hope that new treatment methods will be able to improve both clinical signs and health-related quality of life in patients with AA. In order to assess the outcomes of trials on these new treatment methods, it would be helpful when further development and validation of AA-specific instruments is being encouraged and also conducted.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1614-1621Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Afford R, Leung AKC, Lam JM. Pediatric alopecia areata. Curr Pediatr Rev 2021; 17: 45-54.
Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol 2015; 8: 397-403.
Lee HH, Gwillim E, Patel KR et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 2020; 82: 675-682.
Rencz F, Gulácsi L, Péntek M, Wikonkál N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 561-571.
Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata - a promising new dawn? Expert Rev Clin Pharmacol 2020; 13: 43-51.
Ramot Y, Zlotogorski A. JAK inhibitors for the treatment of alopecia areata. Harefuah 2020; 159: 38-42.
Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative Study. Dermatology 2019; 235: 130-136.
Finlay AY, Salek MS, Abeni D et al. Why quality of life measurement is important in dermatology clinical practice: an expert-based opinion statement by the EADV Task Force on Quality of Life. J Eur Acad Dermatol Venereol 2017; 31: 424-431.
Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al. Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2018; 32: 194-208.
Chernyshov PV, Tomas-Aragones L, Manolache L et al. Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life. J Eur Acad Dermatol Venereol 2017; 31: 576-593.
Chernyshov P, de Korte J, Tomas-Aragones L, Lewis-Jones S; EADV Quality of Life Task Force. EADV Taskforce's recommendations on measurement of health-related quality of life in paediatric dermatology. J Eur Acad Dermatol Venereol 2015; 29: 2306-2316.
Prinsen C, de Korte J, Augustin M et al. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013; 27: 1195-1203.
Sampogna F, Finlay AY, Salek SS et al. Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. J Eur Acad Dermatol Venereol 2017; 31: 1429-1439.
Chernyshov PV, Tomas-Aragones L, Manolache L et al. Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol 2018; 32: 1410-1419.
Chernyshov PV, Lallas A, Tomas-Aragones L et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol 2019; 33: 816-827.
Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2019; 33: 1633-1643.
Chernyshov PV, John SM, Tomas-Aragones L et al. Quality of life measurement in occupational skin diseases. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Occupational Skin Disease. J Eur Acad Dermatol Venereol 2020; 34: 1924-1931.
Finlay AY, Chernyshov PV, Tomas Aragones L et al. Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol 2021; 35: 318-328.
Chernyshov PV, Tomas-Aragones L, Augustin M et al. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2020; 34: 1666-1671.
Finlay AY. Quimp: a word meaning "quality of life impairment". Acta Derm Venereol 2017; 97: 546-547.
Chernyshov PV, Linder MD, Pustišek N et al. Quimp (quality of life impairment): an addition to the quality of life lexicon. J Eur Acad Dermatol Venereol 2018; 32: e181-e182.
Güleç AT, Tanriverdi N, Dürü C, Saray Y, Akçali C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol 2004; 43: 352-356.
Price VH, Hordinsky MK, Olsen EA et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol 2008; 58: 395-402.
Nijsten T, Sampogna F, Abeni D. Categorization of Skindex-29 scores using mixture analysis. Dermatology 2009; 218: 151-154.
Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J. Hypnosis in refractory alopecia areata significantly improves depression, anxiety, and life quality but not hair regrowth. J Am Acad Dermatol 2010; 62: 517-518.
Dubois M, Baumstarck-Barrau K, Gaudy-Marqueste C et al. Quality of life in alopecia areata: a study of 60 cases. J Invest Dermatol 2010; 130: 2830-2833.
Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J. Hypnosis and alopecia areata: long-term beneficial effects on psychological well-being. Acta Derm Venereol 2011; 91: 35-39.
Reid EE, Haley AC, Borovicka JH et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 2012; 66: e97-e102.
Al-Mutairi N, Eldin ON. Clinical profile and impact on quality of life: seven years experience with patients of alopecia areata. Indian J Dermatol Venereol Leprol 2011; 77: 489-493.
Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol 2012; 22: 531-536.
Fabbrocini G, Panariello L, De Vita V et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol 2013; 27: e276-e281.
Ghajarzadeh M, Ghiasi M, Kheirkhah S. Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata. Acta Med Iran 2012; 50: 511-515.
Staumont-Sallé D, Vonarx M, Lengrand F, Segard M, Delaporte E. Pulse corticosteroid therapy for alopecia areata: long-term outcome after 10 years. Dermatology 2012; 225: 81-87.
Kluger N, Jokinen M, Krohn K, Ranki A. What is the burden of living with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) in 2012? A health-related quality-of-life assessment in Finnish patients. Clin Endocrinol (Oxf) 2013; 79: 134-141.
Inui S, Inoue T, Itami S. Psychosocial impact of wigs or hairpieces on perceived quality of life level in female patients with alopecia areata. J Dermatol 2013; 40: 225-226.
Masmoudi J, Sellami R, Ouali U et al. Quality of life in alopecia areata: a sample of tunisian patients. Dermatol Res Pract 2013; 2013: 983804.
Bilgiç Ö, Bilgiç A, Bahalı K, Bahali AG, Gürkan A, Yılmaz S. Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata. J Eur Acad Dermatol Venereol 2014; 28: 1463-1468.
Shi Q, Duvic M, Osei JS et al. Health-related quality of life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data. J Investig Dermatol Symp Proc 2013; 16: S49-50.
Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc 2013; 16: S51-S52.
Qi S, Xu F, Sheng Y, Yang Q. Assessing quality of life in alopecia areata patients in China. Psychol Health Med 2015; 20: 97-102.
Erfan G, Albayrak Y, Yanik ME et al. Distinct temperament and character profiles in first onset vitiligo but not in alopecia areata. J Dermatol 2014; 41: 709-715.
de Hollanda TR, Sodré CT, Brasil MA, Ramos-E-Silva M. Quality of life in alopecia areata: a case-control study. Int J Trichology 2014; 6: 8-12.
Janković S, Perić J, Maksimović N et al. Quality of life in patients with alopecia areata: a hospital-based cross-sectional study. J Eur Acad Dermatol Venereol 2016; 30: 840-846.
Karia SB, De Sousa A, Shah N, Sonavane S, Bharati A. Psychiatric morbidity and quality of life in skin diseases: a comparison of alopecia areata and psoriasis. Ind Psychiatry J 2015; 24: 125-128.
Yu NL, Tan H, Song ZQ, Yang XC. Illness perception in patients with androgenetic alopecia and alopecia areata in China. J Psychosom Res 2016; 86: 1-6.
Zhang M, Zhang N. Quality of life assessment in patients with alopecia areata and androgenetic alopecia in the People's Republic of China. Patient Prefer Adherence 2017; 11: 151-155.
Gallo R, Chiorri C, Gasparini G, Signori A, Burroni A, Parodi A. Can mindfulness-based interventions improve the quality of life of patients with moderate/severe alopecia areata? A prospective pilot study. J Am Acad Dermatol 2017; 76: 757-759.
Essa N, Awad S, Nashaat M. Validation of an Egyptian Arabic version of skindex-16 and quality of life measurement in Egyptian patients with skin disease. Int J Behav Med 2018; 25: 243-251.
Christensen T, Yang JS, Castelo-Soccio L. Bullying and quality of life in pediatric alopecia areata. Skin Appendage Disord 2017; 3: 115-118.
Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. J Am Acad Dermatol 2018; 78: 597-599.e2.
Okhovat JP, Grogan T, Duan L, Goh C. Willingness to pay and quality of life in alopecia areata. J Am Acad Dermatol 2017; 77: 1183-1184.
Bolotnaja L, Serbina I. Adaptive regulatory mechanisms of alopecia areata. Georgian Med News 2017; 272: 75-80.
Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc 2018; 19: S41-S46.
Willemse H, van der Doef M, van Middendorp H. Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. J Health Psychol 2019; 24: 1461-1472.
Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol 2018; 79: 556-558.e1.
Jun M, Keum DI, Lee S, Kim BJ, Lee WS. Quality of life with alopecia areata versus androgenetic alopecia assessed using hair specific Skindex-29. Ann Dermatol 2018; 30: 388-391.
Abedini R, Hallaji Z, Lajevardi V, Nasimi M, Karimi Khaledi M, Tohidinik HR. Quality of life in mild and severe alopecia areata patients. Int J Womens Dermatol 2017; 4: 91-94.
Gonul M, Cemil BC, Ayvaz HH, Cankurtaran E, Ergin C, Gurel MS. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata. An Bras Dermatol 2018; 93: 651-658.
Yoon HS, Bae JM, Yeom SD et al. Factors affecting the psychosocial distress of patients with alopecia areata: a nationwide study in Korea. J Invest Dermatol 2019; 139: 712-715.
Russo PM, Fino E, Mancini C, Mazzetti M, Starace M, Piraccini BM. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. J Eur Acad Dermatol Venereol 2019; 33: 608-611.
Putterman E, Patel DP, Andrade G et al. Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective, cross-sectional study. J Am Acad Dermatol 2019; 80: 1389-1394.
Li SJ, Huang KP, Joyce C, Mostaghimi A. The impact of alopecia areata on sexual quality of life. Int J Trichology 2018; 10: 271-274.
Lai VWY, Chen G, Gin D, Sinclair R. Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol 2019; 81: 694-701.
Lai VWY, Chen G, Sinclair R. Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata. J Dermatolog Treat 2021; 32: 250-257.
Titeca G, Goudetsidis L, Francq B et al. 'The psychosocial burden of alopecia areata and androgenetica': a cross-sectional multicentre study among dermatological out-patients in 13 European countries. J Eur Acad Dermatol Venereol 2020; 34: 406-411.
Vélez-Muñiz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-Sánchez MA. Psychological profile and quality of life of patients with alopecia areata. Skin Appendage Disord 2019; 5: 293-298.
Toraih EA, Ameen HM, Hussein MH et al. Association of autoimmune regulator gene Rs2075876 variant, but not gene expression with alopecia areata in males: a case-control study. Immunol Invest 2020; 49: 146-165.
Aldhouse NVJ, Kitchen H, Knight S et al. "'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes 2020; 4: 76.
Le Duff F, Bouaziz JD, Fontas E et al. Low dose IL-2 for treating moderate to severe alopecia areata. A 52 weeks multicenter prospective placebo-controlled study assessing its impact on T regulatory cells and natural killer populations. J Invest Dermatol 2020; 141: 933-936.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
Sampogna F, Tabolli S, Abeni D. Impact of different skin conditions on quality of life. G Ital Dermatol Venereol 2013; 148: 255-261.
Chernyshov PV, Sampogna F, Pustišek N et al. Validation of the dermatology-specific proxy instrument the Infants and Toddlers Dermatology Quality of Life. J Eur Acad Dermatol Venereol 2019; 33: 1405-1411.
Chernyshov PV. Dermatological quality of life instruments in children. G Ital Dermatol Venereol 2013; 148: 277-285.
Chernyshov PV. Gender differences in health-related and family quality of life in young children with atopic dermatitis. Int J Dermatol 2012; 51: 290-294.
Chernyshov PV, Ho RC, Monti F et al. Gender differences in self-assessed health-related quality of life in children with atopic dermatitis. J Clin Aesthet Dermatol 2016; 9: 19-24.
Chernyshov PV. The evolution of quality of life assessment and use in dermatology. Dermatology 2019; 235: 167-174.
Chernyshov PV, Tomas Aragones L, Salavastru CM et al. Selection process of measures for core outcome set should utilize the highest methodology level and should be maximally free of bias. Comment on 'IDQoL, CDLQI and the 45-item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: a group discussion study'. J Eur Acad Dermatol Venereol 2021; 35: e208-e209.
Lee YB, Lee WS. Alopecia areata and itch: a retrospective analysis of 312 cases. J Eur Acad Dermatol Venereol 2019; 33: e317-e319.
Fischer TW, Schmidt S, Strauss B, Elsner P. Hairdex: a tool for evaluation of diseasespecific quality of life in patients with hair diseases. Hautarzt 2001; 52: 219-227.
Han SH, Byun JW, Lee WS et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol 2012; 24: 311-318.
Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002; 138: 803-807.